Abstract P012: Serum Galectin 3 is Positively Associated with Heart Failure Risk in Male Physicians
Background: Previous studies suggest that galectin-3 (Gal-3) may mediate the effects of macrophage activation and myocardial fibrosis on the pathogenesis of heart failure (HF). While Gal-3 has been reported as prognostic factor in HF patients, limited data are available on the role of Gal-3 in the development of HF.
Objective: To test the hypothesis that serum Gal-3 is positively associated with the risk of HF.
Methods: Prospective nested-case control study (n=462 cases and 462 controls) within the Physicians’ Health Study. For each case of HF, we randomly selected one control among subjects that were alive and free of HF at the time of index case occurrence and matched on age, race, and time of blood collection. Gal-3 was measured using ELISA and we used conditional logistic regression to compute adjusted odds ratios.
Results: Mean age was 58.3 y and median Gla-3 was 4.50 (IQR: 3.32-5.63) ng/ml. Gal-3 was positively correlated with C-reactive protein and age in the control series. Each standard deviation (2.2 ng/ml) higher Gal-3 was associated with 17% higher odds of HF (95% CI: 1% to 35%) after adjustment for matching factors, body mass index, diabetes, atrial fibrillation, hypertension, and C-reactive protein (Figure 1).
Conclusion: Our data are consistent with a positive association between Gal-3 and HF risk in US male physicians. If confirmed in future studies, Gal-3 could help identify people at risk of developing HF.
- © 2013 by American Heart Association, Inc.